Midwest Heart Foundation

Lombard, Illinois 60148

0 studies enrolling now · 16 studies all time

What they study most

Acute Coronary Syndrome, Angina Pectoris, Angioplasty, Transluminal, Percutaneous Coronary, Cardiovascular Disease, Chronic Heart Failure, Chronic Total Occlusion of Coronary Artery, Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Restenosis, Coronary Stenosis, Heart Failure

Studies at this site

• XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort — Completed
• Promote Q Cardiac Resynchronization Therapy Defibrillator (CRT-D) and Quartet Left Ventricular Heart Lead Study — Completed
• Safety and Efficacy Study of the QuickFlex Micro Model 1258T Left Heart Pacing Lead — Completed
• DEfibrillators To REduce Risk by MagnetIc ResoNance Imaging Evaluation — Stopped early
• Phase III Acute Coronary Syndrome — Stopped early
• DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension — Completed
• DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension — Stopped early
• Drug Compliance and Quality of Life in Patients With Heart Failure Dosed With Either Once-daily or Twice-daily Coreg — Completed
• Angiogenesis in Women With Angina Pectoris Who Are Not Candidates for Revascularization — Status unconfirmed
• Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (HF) (REDUCEhf) — Completed
• Prospective Evaluation of Elastic Restraint to LESSen the Effects of Heart Failure (PEERLESS-HF) Trial — Stopped early
• GORE VIABAHN ENDOPROSTHESIS Peripheral Vascular Disease Study — Completed
• Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stents to Treat De Novo Coronary Lesions — Completed
• TAXUS ARRIVE 2: A Multi-Center Safety Surveillance Program — Completed
• The SEPIA-PCI Trial: Otamixaban in Comparison to Heparin in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention — Completed
• To Find the Best Dose of pVGI.1(VEGF2) to Benefit Angina Patients When Given With an Experimental Injection Catheter — Status unconfirmed